Gibson Dunn & Crutcher has advised XOMA Royalty Corporation, and Duane Morris LLP has advised Leerink Partners LLC. XOMA Royalty Corporation has established two at-the-market facilities,...
XOMA Royalty Corporation Launches Common Stock Offering Worth $75 Million
Arrowhead and Novartis Sign Global Licensing Agreement for Preclinical RNA Therapy
Gibson Dunn has advised Arrowhead Pharmaceuticals on the deal. Arrowhead Pharmaceuticals and Novartis have entered into a global license and collaboration agreement concerning ARO-SNCA, Arrowhead’s preclinical...
Sanofi Acquires Greater China Rights to Arrowhead’s RNAi Therapeutic Candidate from Visirna Therapeutics
Gibson Dunn has advised Arrowhead Pharmaceuticals on the deal. An asset purchase agreement has been executed under which Sanofi will acquire the rights to develop and...
Majority Investment in AIA Contract Documents by Welsh, Carson, Anderson & Stowe
Cantor Fitzgerald and Ropes & Gray have advised Welsh, Carson, Anderson & Stowe. Houlihan Lokey, Piper Sandler, and Gibson Dunn have advised AIA Contract Documents and...
HealthCare Royalty and Blue Owl Capital Acquire BridgeBio Pharma’s BEYONTTRA Royalty Interest for $300 Million
Gibson Dunn has advised HealthCare Royalty and Blue Owl Capital, and Latham & Watkins has advised BridgeBio Pharma. HealthCare Royalty and Blue Owl Capital have acquired...
Azimut Group’s Acquisition of a Controlling Interest in HighPost Capital
Sidley Austin is advising Azimut Group on the transaction, and Gibson Dunn & Crutcher is advising HighPost Capital. Azimut Group, one of Europe’s largest independent asset...
Olipop’s $50 Million Series C Financing Round
Gibson Dunn & Crutcher advised J.P. Morgan on the transaction. Olipop, a prebiotic beverage company, raised $50 million in a Series C funding round that valued...
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
GlycoMimetics’ Acquisition of Crescent Biopharma
Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
Tower Arch Capital’s Recapitalization of ACS Manufacturing
Gibson, Dunn & Crutcher advised Tower Arch Capital on the transaction, and Jackson Walker advised ACS Manufacturing. Tower Arch Capital announced that it has recapitalized ACS...
Comply365’s Acquisition of Qualtero
Gibson, Dunn & Crutcher, Willkie Farr & Gallagher and Goldfarb Gross Seligman advised Comply365, LLC on the transaction, DLA Piper and Barnea Jaffa Lande & Co....
Ocumension Therapeutics’ Acquisition of Alcon’s Rights
Gibson, Dunn & Crutcher advised Alcon Inc. on the deal, and Morrison & Foerster advised OcuMension Therapeutics. OcuMension Therapeutics (“OcuMension”), a Hong Kong-listed, China-based ophthalmic pharmaceutical...